Navigation Links
Neurocrine Biosciences Reports Third Quarter 2008 Results
Date:10/28/2008

SAN DIEGO, Calif., Oct. 28 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the quarter ended September 30, 2008. For the third quarter of 2008, the Company reported a net loss of $17.7 million, or $(0.46) per share compared with a net loss of $27.2 million, or $(0.72) per share, for the same period in 2007. For the nine months, the Company reported a net loss of $59.8 million, or $(1.56) per share, as compared to $79.3 million, or $(2.09) per share, for the same period last year.

Revenues for the third quarter of 2008 were $0.8 million compared with $0.5 million for the same period last year. Revenues for the nine months ended September 30, 2008 were $3.2 million, compared with $0.7 million for the same period in 2007. The increase in revenues is primarily due to revenues recognized in 2008 under collaboration agreements with GlaxoSmithKline (GSK) and Dainippon Sumitomo Pharma Co., Ltd.

Research and development expenses decreased to $13.0 million during the third quarter of 2008 compared with $19.8 million for the same period in 2007. For the nine months ended September 30, 2008, research and development expenses were $43.4 million, compared to $57.6 million for the same period last year. The decrease in research and development expenses is primarily due to cost savings related to our restructuring in the fourth quarter of 2007.

General and administrative expenses were $3.5 million for the third quarter of 2008 and $9.6 million during the same period last year. For the nine months ended September 30, 2008, general and administrative expenses were $16.4 million, compared to $26.7 million for the first nine months of 2007. The reduction in general and admin
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Webcast Alert: Neurocrine Announces 3Q 08 Financial Results
2. Neurocrine Biosciences to Present at the Oppenheimer 19th Annual Healthcare Conference
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2008 Financial Results
4. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
5. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
6. Neurocrine Biosciences Reports Second Quarter 2008 Results
7. Neurocrine Biosciences Announces Conference Call and Webcast To Present Second Quarter 2008 Financial Results
8. Neurocrine Biosciences to Present at the 2008 Citi Investment Research Global Health Care Conference
9. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2008 Financial Results
10. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2007 Financial Results
11. Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... The “Molecular Diagnostic Market by ... INAAT, DNA Sequencing), End User (Hospital, Laboratories), & ... Forecast to 2018” provides a detailed overview of ... trends, and strategies impacting the global molecular diagnostics ... the revenue and share analysis. , The global ...
(Date:10/27/2014)... 27, 2014 Called the NOAH ... eliminating several types of pediatric brain cancer. The ... in over 30 years of research and development. ... proves that one mom's determination can make a ... Halloween trick-or-treating, and it’s only fitting that we’ve ...
(Date:10/27/2014)... , Oct. 27, 2014 Pressure BioSciences, ... worldwide leader in the development and sale of ... sciences research market, today announced that Professor ... novel, accurate, highly reproducible, and robust method to ... high-throughput protein analysis on small needle biopsy samples ...
(Date:10/27/2014)... Investor-Edge has initiated coverage on ... NBIX ), Insmed Inc. (NASDAQ: INSM ), ... Corporation (NASDAQ: DYAX ), and Oncothyreon Inc. ... be accessed at: http://investor-edge.com/register . On ... 4,483.72, up 0.69%, the Dow Jones Industrial Average advanced ...
Breaking Biology Technology:Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 2Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 3Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 4Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 5FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 2FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 3Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 2Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 3Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 4Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 5Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 2Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 3Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 4Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 5
... - Strong R&D investments, especially in EHT Dx21 and EHT 0202 clinical, ... achieved for EHT Dx21, - Start of Phase IIa ... collaboration with Allergan and extension, until end 2011, ... Board, - New positioning of Genomic Services and of the SpliceArray(TM) ...
... in prominence as viable vehicle and jet fuel feedstockGREAT ... and researchers of camelina have formed the first trade ... America. The North American Camelina Trade Association (NACTA) ... of new markets for camelina - a relatively new ...
... Rates Under 1 Percent Since 2000,Partnership Will Target Acceleration and Commercialization ... ... Philippines (vocus) March 3, 2009 -- DuPont and the ... to boost rice yields. The Scientific Know-How and Exchange Program ...
Cached Biology Technology:ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 2ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 3ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 4ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 5ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 6ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 7ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 8ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 9ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 10ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 11New Trade Association Formed for North America Camelina Industry 2New Trade Association Formed for North America Camelina Industry 3DuPont and International Rice Research Institute Partner to Boost Rice Yields 2DuPont and International Rice Research Institute Partner to Boost Rice Yields 3
(Date:10/29/2014)... City on September 19, 2014, leading geneticist and humanitarian ... Genome Sciences and Medicine at the University of Washington ... Tel Aviv University, was awarded the 2014 Lasker-Koshland Special ... her honorary degree from TAU, Prof. King was the ... and for the past 18 years she has been ...
(Date:10/29/2014)... reveals new research potential of the Barcode of ... in the Biodiversity Data Journal ... format and imported these into a human-readable text developed ... (PWT). Data were used to study the species distributions ... Microgastrinae subfamily. , BOLD is originally designed to support ...
(Date:10/29/2014)... international Cancer Genomics of the Kidney consortium ( ... cancer and exposure to aristolochic acid, an ingredient ... Nature Communications , have important implications for ... 140,000 people every year, and in Central Europe ... of the International Cancer Genome Consortium (ICGC), has ...
Breaking Biology News(10 mins):Geneticist and humanitarian: Prof. Mary-Claire King receives Lasker Award 2Go straight and publish: From Barcode of Life Data Systems to scholarly publishing systems 2Kidney cancer in Central Europe 2
... (June 28 2013) A study carried out in India ... bone marrow stem cells in patients with type 2 ... when compared to a control group of TD2M patients ... , The study appears as an early e-publication for ...
... make a big difference. A "left-handed" molecule of a ... its mirror-image "right-handed" counterpart could be completely inactive. That,s ... crucial: Living organisms are made only from left-handed amino ... Now, a team of scientists at the U.S. ...
... the late spring, the 4000 elk of the Clarks ... following the greening grass into the highlands of the ... on vegetation fed by snowmelt. It,s a short trip ... uncommonly free of roads, fences, metropolitan areas, and other ...
Cached Biology News:Type 2 diabetes patients transplanted with own bone marrow stem cells reduces insulin use 2Tiny nanocubes help scientists tell left from right 2Tiny nanocubes help scientists tell left from right 3Declining fortunes of Yellowstone's migratory elk 2Declining fortunes of Yellowstone's migratory elk 3Declining fortunes of Yellowstone's migratory elk 4
Vitellogenin (Japanese medaka) Standard...
nuclear RNA export factor 1, mRNA...
... analysis of gene expression) technology ... Expression profiles generated by SAGE ... low-abundance transcripts making it possible ... I-SAGE Kit is designed to ...
The Captivate Disposable Sample Chamber is designed for use with the Captivate magnetic yoke assembly (C-24700) and can be used with our Captivate ferrofluid conjugates (C-21473 C-21474 C-21476) or ...
Biology Products: